Stock Scorecard



Stock Summary for Capricor Therapeutics Inc (CAPR) - $9.93 as of 7/1/2025 3:23:41 PM EST

Total Score

9 out of 30

Safety Score

38 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CAPR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CAPR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CAPR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CAPR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CAPR (38 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CAPR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR - Capricor Therapeutics ( NASDAQ:CAPR ) 6/28/2025 2:00:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR - Capricor Therapeutics ( NASDAQ:CAPR ) 6/28/2025 2:00:00 PM
Capricor ( CAPR ) Moves 20.4% Higher: Will This Strength Last? 6/25/2025 12:56:00 PM
FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy - Capricor Therapeutics ( NASDAQ:CAPR ) 6/24/2025 6:51:00 PM
Why Is Capricor Therapeutics Stock Trading Lower On Monday? - Capricor Therapeutics ( NASDAQ:CAPR ) 6/23/2025 4:46:00 PM
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients - Capricor Therapeutics ( NASDAQ:CAPR ) 6/20/2025 7:11:00 PM
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy 6/20/2025 1:25:00 PM
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aptevo Therapeutics ( NASDAQ:APVO ) , AIRO Group Holdings ( NASDAQ:AIRO ) 6/20/2025 12:01:00 PM
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Aptevo Therapeutics ( NASDAQ:APVO ) , Arqit Quantum ( NASDAQ:ARQQ ) 6/20/2025 10:01:00 AM
Exosome Research Market is expected to generate a revenue of USD 646.52 Million by 2032, Globally, at 13.93% CAGR: Verified Market Research® 6/19/2025 2:15:00 PM

Financial Details for CAPR

Company Overview

Ticker CAPR
Company Name Capricor Therapeutics Inc
Country USA
Description Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 9.93
Price 4 Years Ago 2.93
Last Day Price Updated 7/1/2025 3:23:41 PM EST
Last Day Volume 2,085,097
Average Daily Volume 2,971,853
52-Week High 23.40
52-Week Low 3.52
Last Price to 52 Week Low 182.10%

Valuation Measures

Trailing PE N/A
Industry PE 22.32
Sector PE 40.59
5-Year Average PE -8.33
Free Cash Flow Ratio 15.76
Industry Free Cash Flow Ratio 17.78
Sector Free Cash Flow Ratio 32.59
Current Ratio Most Recent Quarter 6.55
Total Cash Per Share 0.63
Book Value Per Share Most Recent Quarter 2.80
Price to Book Ratio 4.00
Industry Price to Book Ratio 34.87
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 29.35
Industry Price to Sales Ratio Twelve Trailing Months 122.74
Sector Price to Sales Ratio Twelve Trailing Months 35.45
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 45,707,800
Market Capitalization 453,878,454
Institutional Ownership 40.97%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -81.56%
Reported EPS 12 Trailing Months -1.37
Reported EPS Past Year -0.53
Reported EPS Prior Year -1.20
Net Income Twelve Trailing Months -55,066,000
Net Income Past Year -40,467,000
Net Income Prior Year -22,288,000
Quarterly Revenue Growth YOY -7.90%
5-Year Revenue Growth 85.83%
Operating Margin Twelve Trailing Months -329.90%

Balance Sheet

Total Cash Most Recent Quarter 28,794,503
Total Cash Past Year 11,286,996
Total Cash Prior Year 14,694,857
Net Cash Position Most Recent Quarter 25,418,244
Net Cash Position Past Year 7,910,737
Long Term Debt Past Year 3,376,259
Long Term Debt Prior Year 3,376,259
Total Debt Most Recent Quarter 3,376,259
Equity to Debt Ratio Past Year 0.98
Equity to Debt Ratio Most Recent Quarter 0.97
Total Stockholder Equity Past Year 145,462,336
Total Stockholder Equity Prior Year 22,601,467
Total Stockholder Equity Most Recent Quarter 127,645,467

Free Cash Flow

Free Cash Flow Twelve Trailing Months -47,175,766
Free Cash Flow Per Share Twelve Trailing Months -1.03
Free Cash Flow Past Year -41,534,717
Free Cash Flow Prior Year -27,644,078

Options

Put/Call Ratio 0.57
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.23
MACD Signal 0.00
20-Day Bollinger Lower Band 6.80
20-Day Bollinger Middle Band 11.33
20-Day Bollinger Upper Band 15.85
Beta 0.85
RSI 51.20
50-Day SMA 12.01
150-Day SMA 7.17
200-Day SMA 6.35

System

Modified 6/30/2025 7:57:04 PM EST